HDAC6 and non-small cell lung carcinoma: Our proof-of-concept was highlighted with 2-amino benzamide-based HDAC6 inhibitor dimers that exhibit great HDAC6 inhibition activity (3.9–15.4 nM), good HDAC1/6 selectivity (95–577), and excellent cytotoxicity against human hormone-resistant prostate cancer (HRPC) PC-3 and non-small cell lung cancer (NSCLC) A549 cell lines (5.9–11.3 and 6.6–17.9 μM, respectively) while simultaneously inducing HDAC6 degradation.